Soren Lehmann

Publications
CV
Public outreach and news

Articles

Article: LEUKEMIA & LYMPHOMA. 2024;65(10):1493-1501
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
Abe C; Keto J; Lilja M; Konradsen M; Mesterton J; Hoglund M; Lazarevic V; Lehmann S; Juliusson G
Article: NPJ PRECISION ONCOLOGY. 2024;8(1):38
Delineating functional and molecular impact of ex vivo sample handling in precision medicine
Struyf N; Osterroos A; Vesterlund M; Arnroth C; James T; Sunandar S; Mermelekas G; Bohlin A; Hamberg Levedahl K; Bengtzen S; Jafari R; Orre LM; Lehtio J; Lehmann S; Ostling P; Kallioniemi O; Seashore-Ludlow B; Erkers T
Article: NATURE CANCER. 2023;4(10):1474-1490
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
Giannakopoulou E; Lehander M; Virding Culleton S; Yang W; Li Y; Karpanen T; Yoshizato T; Rustad EH; Nielsen MM; Bollineni RC; Tran TT; Delic-Sarac M; Gjerdingen TJ; Douvlataniotis K; Laos M; Ali M; Hillen A; Mazzi S; Chin DWL; Mehta A; Holm JS; Bentzen AK; Bill M; Griffioen M; Gedde-Dahl T; Lehmann S; Jacobsen SEW; Woll PS; Olweus J
Article: LEUKEMIA. 2023;37(9):1830-1841
Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells
Palau A; Segerberg F; Lidschreiber M; Lidschreiber K; Naughton AJ; Needhamsen M; Jung LA; Jagodic M; Cramer P; Lehmann S; Carlsten M; Lennartsson A
Article: BLOOD. 2023;142(1):73-89
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
Dolinska M; Cai H; Mansson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-SF; Deneberg S; Soederlund S; Jaedersten M; Ungerstedt J; Tobiasson M; Ostman A; Mustjoki S; Stenke L; Le Blanc K; Hellstroem-Lindberg E; Lehmann S; Ekblom M; Olsson-Stroemberg U; Sigvarosson M; Qian H
Article: LEUKEMIA. 2023;37(5):1103-1112
Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective
Berggren DM; Garelius H; Hjelm PW; Nilsson L; Rasmussen B; Weibull CE; Lambe M; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ejerblad E
Article: HAEMATOLOGICA. 2023;108(4):1015-1025
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
Nilsson C; Linde F; Hulegardh E; Garelius H; Lazarevic V; Antunovic P; Cammenga J; Deneberg S; Eriksson A; Jadersten M; Bjorkvall CK; Mollgard L; Wennstrom L; Olander E; Hoglund M; Juliusson G; Lehmann S
Article: NPJ PRECISION ONCOLOGY. 2023;7(1):32
Prediction model for drug response of acute myeloid leukemia patients
Trac QT; Pawitan Y; Mou T; Erkers T; Ostling P; Bohlin A; Osterroos A; Vesterlund M; Jafari R; Siavelis I; Backvall H; Kiviluoto S; Orre LM; Rantalainen M; Lehtio J; Lehmann S; Kallioniemi O; Vu TN
Article: BLOOD. 2023;141(7):800-805
Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions
Ryland GL; Umeda M; Holmfeldt L; Lehmann S; Herlin MK; Ma J; Khanlari M; Rubnitz JE; Ries RE; Kosasih HJ; Ekert PG; Goh HN; Tiong IS; Grimmond SM; Haferlach C; Day RB; Ley TJ; Meshinchi S; Ma X; Blombery P; Klco JM
Article: JOURNAL OF INTERNAL MEDICINE. 2022;292(6):925-940
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial
Jadersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzen S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Ostling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Hoglund M; Henter J-I; Herold N
Article: HAEMATOLOGICA. 2022;107(8):1786-1795
A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
Arruda LCM; Stikvoort A; Lambert M; Jin L; Rivera LS; Alves RMP; de Moura TR; Mim C; Lehmann S; Axelsson-Robertson R; Dick JE; Mattsson J; Onfelt B; Carlsten M; Uhlin M
Article: NATURE COMMUNICATIONS. 2022;13(1):4033
Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays.
Chen L; Eriksson A; Weström S; Pandzic T; Lehmann S; Cavelier L; Landegren U
Article: HAEMATOLOGICA. 2022;107(7):1528-1537
A risk score based on real-world data to predict early death in acute promyelocytic leukemia
Osterroos A; Maia T; Eriksson A; Jadersten M; Lazarevic V; Wennstrom L; Antunovic P; Cammenga J; Deneberg S; Lorenz F; Mollgard L; Uggla B; Olander E; Aguiar E; Trigo F; Hoglund M; Juliusson G; Lehmann S
Article: NATURE BIOTECHNOLOGY. 2022;40(4):488-498
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
Ali M; Giannakopoulou E; Li Y; Lehander M; Culleton SV; Yang W; Knetter C; Odabasi MC; Bollineni RC; Yang X; Foldvari Z; Boschen M-L; Taraldsrud E; Stronen E; Toebes M; Hillen A; Mazzi S; de Ru AH; Janssen GMC; Kolstad A; Tjonnfjord GE; Lie BA; Griffioen M; Lehmann S; Osnes LT; Buechner J; Garcia KC; Schumacher TN; van Veelen PA; Leisegang M; Jacobsen SEW; Woll P; Olweus J
Article: CANCER RESEARCH COMMUNICATIONS. 2022;2(3):182-201
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner
Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickstrom M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson L-G
Article: CANCER RESEARCH. 2021;81(22):5733-5744
MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia
Sanjiv K; Calderon-Montano JM; Pham TM; Erkers T; Tsuber V; Almlof I; Hoglund A; Heshmati Y; Seashore-Ludlow B; Danda AN; Gad H; Wiita E; Gokturk C; Rasti A; Friedrich S; Centio A; Estruch M; Vatsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Monch K; Garnett MJ; Ostling P; Walfridsson J; Helleday T; Berglund UW
Article: HAEMATOLOGICA. 2021;106(10):2566-2577
Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
Hultmark S; Baudet A; Schmiderer L; Prabhala P; Palma-Tortosa S; Sanden C; Fioretos T; Sasidharan R; Larsson C; Lehmann S; Juliusson G; Ek F; Magnusson M
Article: LEUKEMIA & LYMPHOMA. 2021;62(8):1973-1981
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study
Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf A; Deneberg S; Jadersten M; Antunovic P; Cammenga J; Mollgard L; Wennstrom L; Olander E; Ehinger M; Fogelstrand L; Hoglund M; Lazarevic VL
Article: GENES CHROMOSOMES & CANCER. 2021;60(6):426-433
Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study
Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Hoglund M; Lehmann S; Derolf A; Deneberg S; Antunovic P; Cammenga J; Mollgard L; Wennstrom L; Lilljebjorn H; Rissler M; Fioretos T; Lazarevic VL
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(5):580-588
The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia
Mou T; Pawitan Y; Stahl M; Vesterlund M; Deng W; Jafari R; Bohlin A; Osterroos A; Siavelis L; Backvall H; Erkers T; Kiviluoto S; Seashore-Ludlow B; Ostling P; Orre LM; Kallioniemi O; Lehmann S; Lehtio J; Trung NV
Article: BLOOD ADVANCES. 2021;5(4):1003-1016
Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML
Mareschal S; Palau A; Lindberg J; Ruminy P; Nilsson C; Bengtzen S; Engvall M; Eriksson A; Neddermeyer A; Marchand V; Jansson M; Bjorklund M; Jardin F; Rantalainen M; Lennartsson A; Cavelier L; Gronberg H; Lehmann S
Article: NATURE COMMUNICATIONS. 2021;12(1):1054
Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
Mer AS; Heath EM; Tonekaboni SAM; Dogan-Artun N; Nair SK; Murison A; Garcia-Prat L; Shlush L; Hurren R; Voisin V; Bader GD; Nislow C; Rantalainen M; Lehmann S; Gower M; Guidos CJ; Lupien M; Dick JE; Minden MD; Schimmer AD; Haibe-Kains B
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):474-483
Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study
Berggren DM; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ungerstedt J; Ejerblad E
Article: BLOOD. 2020;136(3):339-352
AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding
Mujahed H; Miliara S; Neddermeyer A; Bengtzen S; Nilsson C; Deneberg S; Cordeddu L; Ekwall K; Lennartsson A; Lehmann S
Article: CLINICAL CANCER RESEARCH. 2020;26(14):3597-3607
RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia
Anande G; Deshpande NP; Mareschal S; Batcha AMN; Hampton HR; Herold T; Lehmann S; Wilkins MR; Wong JWH; Unnikrishnan A; Pimanda JE
Article: GENOME BIOLOGY. 2020;21(1):153
Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs
Do C; Dumont ELP; Salas M; Castano A; Mujahed H; Maldonado L; Singh A; DaSilva-Arnold SC; Bhagat G; Lehman S; Christiano AM; Madhavan S; Nagy PL; Green PHR; Feinman R; Trimble C; Illsley NP; Marder K; Honig L; Monk C; Goy A; Chow K; Goldlust S; Kaptain G; Siegel D; Tycko B
Article: BLOOD CANCER JOURNAL. 2020;10(6):67
Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia
Osterroos A; Bjorklund M; Eriksson A; Lindberg J; Nilsson C; Mareschal S; Rantalainen M; Gronberg H; Lehmann S
Article: BLOOD ADVANCES. 2020;4(6):1094-1101
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting
Juliusson G; Jadersten M; Deneberg S; Lehmann S; Mollgard L; Wennstrom L; Antunovic P; Cammenga J; Lorenz F; Olander E; Lazarevic VL; Hoglund M
Article: EMBO MOLECULAR MEDICINE. 2020;12(3):e10419
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy
Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CBJ; Sandhow L; Kutzner J; Myrberg IH; Bunten SS; Axelsson H; Zhang SM; Rasti A; Makela P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtio J; Rassidakis GZ; Tamm KP; Warpman-Berglund U; Heyman M; Grander D; Lehmann S; Lundback T; Qian H; Henter J-I; Schaller T; Helleday T; Herold N
Article: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(29):2632-2642
Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.
Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas P-Y; Dombret H; Preudhomme C; Micol J-B; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch J-H; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(9):1770-1778
Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting
Nilsson C; Hulegardh E; Garelius H; Mollgard L; Brune M; Wahlin A; Lenhoff S; Frodin U; Remberger M; Hoglund M; Juliusson G; Stockelberg D; Lehmann S
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(10):1094-1101
Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia
Wang M; Lindberg J; Klevebring D; Nilsson C; Lehmann S; Gronberg H; Rantalainen M
Article: SCIENTIFIC REPORTS. 2018;8(1):11293
Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
Hornung R; Jurinovic V; Batcha AMN; Bamopoulos SA; Rothenberg-Thurley M; Amler S; Sauerlands MC; Berdel WE; Woermann BJ; Bohlander SK; Braess J; Hiddemann W; Lehmann S; Mareschal S; Spiekermann K; Metzeler KH; Herold T; Boulesteix A-L
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;181(5):614-627
Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register
Berggren DM; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ejerblad E
Article: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2018;11(1):52
Expression levels of long non-coding RNAs are prognostic for AML outcome
Mer AS; Lindberg J; Nilsson C; Klevebring D; Wang M; Gronberg H; Lehmann S; Rantalainen M
Article: FREE RADICAL BIOLOGY AND MEDICINE. 2018;117:247-257
Selenite and methylseleninic acid epigenetically affects distinct gene sets in myeloid leukemia: A genome wide epigenetic analysis
Khalkar P; Ali HA; Codo P; Diaz Argelich N; Martikainen A; Arzenani MK; Lehmann S; Walfridsson J; Ungerstedt J; Fernandes AP
Article: LEUKEMIA. 2017;31(10):2029-2036
Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling
Wang M; Lindberg J; Klevebring D; Nilsson C; Mer AS; Rantalainen M; Lehmann S; Gronberg H
Article: CANCER IMMUNOLOGY RESEARCH. 2017;5(8):654-665
Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells
Liu LL; Beziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellstrom-Lindberg E; Soderhall S; Heyman M; Grander D; Malmberg K-J
Article: LEUKEMIA. 2017;31(5):1108-1116
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
Ilander M; Olsson-Stromberg U; Schlums H; Guilhot J; Bruck O; Lahteenmaki H; Kasanen T; Koskenvesa P; Soderlund S; Hoglund M; Markevarn B; Sjalander A; Lotfi K; Dreimane A; Lubking A; Holm E; Bjoreman M; Lehmann S; Stenke L; Ohm L; Gedde-Dahl T; Majeed W; Ehrencrona H; Koskela S; Saussele S; Mahon F-X; Porkka K; Hjorth-Hansen H; Bryceson YT; Richter J; Mustjoki S
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(5):493-500
Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry
Lazarevic VL; Rosso A; Juliusson G; Antunovic P; Derolf AR; Deneberg S; Mollgard L; Uggla B; Wennstrom L; Wahlin A; Hoglund M; Lehmann S; Johansson B
Article: ONCOTARGET. 2017;8(17):28812-28825
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease
Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grovdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellstrom-Lindberg E; Ungerstedt J
Article: BLOOD. 2017;129(7):e13-e25
Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia
Qu Y; Siggens L; Cordeddu L; Gaidzik VI; Karlsson K; Bullinger L; Doehner K; Ekwall K; Lehmann S; Lennartsson A
Article: NATURE MEDICINE. 2017;23(2):256-263
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CBJ; Heshmati Y; Hagenkort A; Kutzner J; Paget BDG; Calderon-Montano JM; Loseva O; Jemth A-S; Bulli L; Axelsson H; Tesi B; Valerie NCK; Hoglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grander D; Lundback T; Kogner P; Henter J-I; Helleday T; Schaller T
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2016;174(1):117-126
Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells
Ali D; Mohammad DK; Mujahed H; Jonson-Videsater K; Nore B; Paul C; Lehmann S
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2015;90(9):800-805
Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia
Lazarevic V; Rosso A; Juliusson G; Antunovic P; Rangert-Derolf A; Lehmann S; Mollgard L; Uggla B; Wennstrom L; Wahlin A; Hoglund M; Johansson B
Article: EXPERIMENTAL HEMATOLOGY. 2015;43(8):609-624
Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis
Eriksson A; Lennartsson A; Lehmann S
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2015;94(5):419-423
Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia
Lazarevic V; Horstedt A-S; Johansson B; Antunovic P; Billstrom R; Derolf A; Lehmann S; Moellgard L; Peterson S; Stockelberg D; Uggla B; Vennstroem L; Wahlin A; Hoeglund M; Juliusson G
Article: LEUKEMIA. 2015;29(5):1084-1091
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet
Lengfelder E; Lo-Coco F; Ades L; Montesinos P; Grimwade D; Kishore B; Ramadan SM; Pagoni M; Breccia M; Huerta AJG; Nloga AM; Gonzalez-Sanmiguel JD; Schmidt A; Lambert J-F; Lehmann S; Di Bona E; Cassinat B; Hofmann W-K; Gorlich D; Sauerland M-C; Fenaux P; Sanz M
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2015;90(3):208-214
Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry
Hulegardh E; Nilsson C; Lazarevic V; Garelius H; Antunovic P; Rangert Derolf A; Mollgard L; Uggla B; Wennstrom L; Wahlin A; Hoglund M; Juliusson G; Stockelberg D; Lehmann S
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(26):2477-2487
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Genovese G; Kaehler AK; Handsaker RE; Lindberg J; Rose SA; Bakhoum SF; Chambert K; Mick E; Neale BM; Fromer M; Purcell SM; Svantesson O; Landen M; Hoeglund M; Lehmann S; Gabriel SB; Moran JL; Lander ES; Sullivan PF; Sklar P; Groenberg H; Hultman CM; McCarroll SA
Article: EPIGENETICS. 2014;9(8):1108-1119
Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes
Qu Y; Lennartsson A; Gaidzik VI; Deneberg S; Karimi M; Bengtzen S; Hoglund M; Bullinger L; Doehner K; Lehmann S
Article: BMC GENOMICS. 2014;15(1):487
Relationship between genome and epigenome - challenges and requirements for future research
Almouzni G; Altucci L; Amati B; Ashley N; Baulcombe D; Beaujean N; Bock C; Bongcam-Rudloff E; Bousquet J; Braun S; Bressac-de Paillerets B; Bussemakers M; Clarke L; Conesa A; Estivill X; Fazeli A; Grgurevic N; Gut I; Heijmans BT; Hermouet S; Houwing-Duistermaat J; Iacobucci I; Ilas J; Kandimalla R; Krauss-Etschmann S; Lasko P; Lehmann S; Lindroth A; Majdic G; Marcotte E; Martinelli G; Martinet N; Meyer E; Miceli C; Mills K; Moreno-Villanueva M; Morvan G; Nickel D; Niesler B; Nowacki M; Nowak J; Ossowski S; Pelizzola M; Pochet R; Potocnik U; Radwanska M; Raes J; Rattray M; Robinson MD; Roelen B; Sauer S; Schinzer D; Slagboom E; Spector T; Stunnenberg HG; Tiligada E; Torres-Padilla M-E; Tsonaka R; Van Soom A; Vidakovic M; Widschwendter M
Article: EPIGENETICS. 2014;9(6):910-917
microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia
Deneberg S; Kanduri M; Ali D; Bengtzen S; Karimi M; Qu Y; Kimby E; Mansouri L; Rosenquist R; Lennartsson A; Lehmann S
Article: BLOOD. 2014;123(17):e79-e89
Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation
Ronnerblad M; Andersson R; Olofsson T; Douagi I; Karimi M; Lehmann S; Hoof I; de Hoon M; Itoh M; Nagao-Sato S; Kawaji H; Lassmann T; Carninci P; Hayashizaki Y; Forrest ARR; Sandelin A; Ekwall K; Arner E; Lennartsson A
Article: BLOOD CANCER JOURNAL. 2014;4(2):e188
Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience
Lazarevic V; Horstedt A-S; Johansson B; Antunovic P; Billstrom R; Derolf A; Hulegardh E; Lehmann S; Mollgard L; Nilsson C; Peterson S; Stockelberg D; Uggla B; Wennstrom L; Wahlin A; Hoglund M; Juliusson G
Article: BLOOD. 2013;122(7):1284-1292
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
Hoglund M; Sandin F; Hellstrom K; Bjoreman M; Bjorkholm M; Brune M; Dreimane A; Ekblom M; Lehmann S; Ljungman P; Malm C; Markevarn B; Myhr-Eriksson K; Ohm L; Olsson-Stromberg U; Sjalander A; Wadenvik H; Simonsson B; Stenke L; Richter J
Article: LEUKEMIA & LYMPHOMA. 2013;54(4):843-850
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grander D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Osterborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(29):3633-3639
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Lehmann S; Bykov VJN; Ali D; Andren O; Cherif H; Tidefelt U; Uggla B; Yachnin J; Juliusson G; Moshfegh A; Paul C; Wiman KG; Andersson P-O
Article: HAEMATOLOGICA. 2012;97(9):1380-1388
A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies
Gronbaek K; Mueller-Tidow C; Perini G; Lehmann S; Treppendahl MB; Mills K; Plass C; Schlegelberger B
Article: BLOOD. 2011;118(20):5573-5582
Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks
Deneberg S; Guardiola P; Lennartsson A; Qu Y; Gaidzik V; Blanchet O; Karimi M; Bengtzen S; Nahi H; Uggla B; Tidefelt U; Hoglund M; Paul C; Ekwall K; Doehner K; Lehmann S
Article: CANCER. 2011;117(18):4238-4246
Hematopoietic Stem Cell Transplantation Rates and Long-Term Survival in Acute Myeloid and Lymphoblastic Leukemia Real-World Population-Based Data From the Swedish Acute Leukemia Registry 1997-2006
Juliusson G; Karlsson K; Lazarevic VL; Wahlin A; Brune M; Antunovic P; Derolf A; Hagglund H; Karbach H; Lehmann S; Mollgard L; Stockelberg D; Hallbook H; Hoglund M
Article: LEUKEMIA. 2011;25(7):1128-1134
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry
Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Mollgard L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennstrom L; Hoglund M; Juliusson G
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;86(3):206-215
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells
Ali D; Jonsson-Videsater K; Deneberg S; Bengtzen S; Nahi H; Paul C; Lehmann S
Article: LEUKEMIA. 2010;24(5):932-941
Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia
Deneberg S; Grovdal M; Karimi M; Jansson M; Nahi H; Corbacioglu A; Gaidzik V; Doehner K; Paul C; Ekstrom TJ; Hellstrom-Lindberg E; Lehmann S
Article: CANCER LETTERS. 2009;282(1):116-123
Selenite is a potent cytotoxic agent for human primary AML cells
Olm E; Jonsson-Videsater K; Ribera-Cortada I; Fernandes AP; Eriksson LC; Lehmann S; Rundlof A-K; Paul C; Bjornstedt M
Article: HAEMATOLOGICA. 2009;94(9):1301-1306
Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells
Akagi T; Shih L-Y; Ogawa S; Gerss J; Moore SR; Schreck R; Kawamata N; Liang D-C; Sanada M; Nannya Y; Deneberg S; Zachariadis V; Nordgren A; Song JH; Dugas M; Lehmann S; Koeffler HP
Article: BLOOD. 2009;113(18):4179-4187
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Juliusson G; Antunovic P; Derolf A; Lehmann S; Mollgard L; Stockelberg D; Tidefelt U; Wahlin A; Hoglund M
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2008;62(3):439-448
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia
Mollgard L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsater K; Fioretos T; Andersson A; Paul C; Lehmann S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;141(4):445-453
Mutated and non-mutated TP53 as targets in the treatment of leukaemia
Nahi H; Selivanova G; Lehmann S; Mollgard L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Article: CANCER. 2008;112(6):1296-1305
Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia
Lehmann S; Ogawa S; Raynaud SD; Sanada M; Nannya Y; Ticchioni M; Bastard C; Kawamata N; Koeffler HP
Article: LEUKEMIA & LYMPHOMA. 2008;49(3):508-516
Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia
Nahi H; Lehmann S
Article: THERAPEUTIC DRUG MONITORING. 2007;29(5):626-631
Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia
Lofgren C; Lehmann S; Jonsson-Videsater K; Mollgard L; Linder O; Tidefelt U; Hassan M; Paul C
Article: LEUKEMIA. 2007;21(9):1931-1936
Common deleted genes in the 5q-syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice
Lehmann S; O'Kelly J; Raynaud S; Funk SE; Sage EH; Koeffler HP
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;132(2):230-236
PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Article: NATURE MEDICINE. 2005;11(6):630-637
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia
Castor A; Nilsson L; Åstrand-Grundström I; Buitenhuis M; Ramirez C; Anderson K; Strömbeck B; Garwicz S; Békássy AN; Schmiegelow K; Lausen B; Hokland P; Lehmann S; Juliusson G; Johansson B; Jacobsen SEW
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;127(3):285-291
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
Article: BIOCHEMICAL PHARMACOLOGY. 2002;63(10):1875-1884
Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity -: Effects on thioredoxin reductase and glutathione reductase
Björkhem-Bergman L; Jönsson K; Eriksson LC; Olsson JM; Lehmann S; Paul C; Björnstedt M
Article: LEUKEMIA & LYMPHOMA. 2002;43(4):851-858
The expression of cellular retinoid binding proteins in non-APL leukemic cells and its association with retinoid sensitivity
Lehmann S; Paul C; Törmä H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2001;66(6):357-364
Effects of arsenic trioxide (As₂O₃) on leukemic cells from patients with non-M3 acute myelogenous leukemia:: studies of cytotoxicity, apoptosis and the pattern of resistance
Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Article: BONE MARROW TRANSPLANTATION. 2000;26(2):187-192
Cardiac systolic function before and after hematopoietic stem cell transplantation
Lehmann S; Isberg B; Ljungman P; Paul C
Article: BONE MARROW TRANSPLANTATION. 2000;25(9):993-996
N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation
Ringdén O; Remberger M; Lehmann S; Hentschke P; Mattsson J; Klaesson S; Aschan J
Article: LEUKEMIA RESEARCH. 2000;24(1):19-25
Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML
Lehmann S; Bengtzen S; Broberg U; Paul C
Show more

All other publications

Letter: LEUKEMIA. 2024;38(3):663-666
The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia
Miliara S; Cozzi E; Zhong X; Chan I; Ekwall K; Lehmann S; Lennartsson A; Bartek J; Kanellis DC
Letter: BLOOD ADVANCES. 2021;5(3):787-790
Impact of treatment delay in acute myeloid leukemia revisited.
Juliusson G; Hagberg O; Lazarevic VL; Lehmann S; Höglund M
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(1):e13-e16
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years
Osterroos A; Eriksson A; Antunovic P; Cammenga J; Deneberg S; Lazarevic V; Lorenz F; Mollgard L; Derolf AR; Uggla B; Wennstrom L; Olander E; Hoglund M; Juliusson G; Lehmann S
Editorial comment: HAEMATOLOGICA. 2020;105(2):249-251
Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people
Juliusson G; Hoglund M; Lehmann S
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;188(1):187-191
Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor
Derolf A; Juliusson G; Benson L; Floisand Y; Lazarevic V; Antunovic P; Mollgard L; Lehmann S; Uggla B; Wahlin A; Hoglund M; Deneberg S
Letter: BLOOD. 2019;134(18):1558-1561
Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period
Juliusson G; Hagberg O; Lazarevic VL; Olander E; Antunovic P; Cammenga J; Wennstrom L; Mollgard L; Brune M; Jadersten M; Deneberg S; Lehmann S; Derolf AR; Hoglund M
Letter: LEUKEMIA. 2017;31(6):1457-1459
Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013
Lehmann S; Deneberg S; Antunovic P; Rangert-Derolf A; Garelius H; Lazarevic V; Myhr-Eriksson K; Mollgard L; Uggla B; Wahlin A; Wennstrom L; Hoglund M; Juliusson G
Letter: LEUKEMIA. 2017;31(3):728-731
Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden
Juliusson G; Abrahamsson J; Lazarevic V; Antunovic P; Derolf A; Garelius H; Lehmann S; Myhr-Eriksson K; Mollgard L; Uggla B; Wahlin A; Wennstrom L; Hoglund M
Letter: BLOOD CANCER JOURNAL. 2016;6(7):e447
An open-label phase I dose-finding study of APR-246 in hematological malignancies
Deneberg S; Cherif H; Lazarevic V; Andersson P-O; von Euler M; Juliusson G; Lehmann S
Letter: HAEMATOLOGICA. 2015;100(6):e223-e225
High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia
Karimi M; Nilsson C; Dimitriou M; Jansson M; Matsson H; Unneberg P; Lehmann S; Kere J; Hellstrom-Lindberg E
Review: ALLERGY. 2008;63(7):842-853
Important research questions in allergy and related diseases:: nonallergic rhinitis:: a GA²LEN paper
Bousquet J; Fokkens W; Burney P; Durham SR; Bachert C; Akdis CA; Canonica GW; Dahlen S-E; Zuberbier T; Bieber T; Bonini S; Bousquet PJ; Brozek JL; Cardell L-O; Crameri R; Custovic A; Demoly P; van Wijk RG; Gjomarkaj M; Holland C; Howarth P; Humbert M; Johnston SL; Kauffmann F; Kowalski ML; Lambrecht B; Lehmann S; Leynaert B; Lodrup-Carlsen K; Mullol J; Niggemann B; Nizankowska-Mogilnicka E; Papadopoulos N; Passalacqua G; Schuenemann HJ; Simon H-U; Todo-Bom A; Toskala E; Valenta R; Wickman M; Zock JP
Meeting abstract: BLOOD. 2007;110(11):161B
Factors affecting long-term survival in non-transplanted acute myeloid leukemia patients
Lof AH; Lehmann S
Meeting abstract: BLOOD. 2007;110(11):133B
Expression of p14ARF in de novo AML with normal karyotype.: Implication on drug resistance and survival
Paul EO; Deneberg S; Lehmann S; Bengtzen S; Nahi H
Meeting abstract: BLOOD. 2004;104(11):501A
Effects of the FLT3 inhibitor PKC 412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
Möllgård L; Bengtzen S; Fioretos T; Andersson A; Paul C; Lehmann S
Review: LAKARTIDNINGEN. 2004;101(4):282-287
[Drug distribution, resistance to cytostatics and disease pathogenesis: many roles of ABC proteins].
Lehmann S; Rane A
Thesis / dissertation: 2002
In vitro studies of retinoids and arsenic in non-M3 acute myeloid leukemia
Lehmann, Sören
Corrigendum: BIOCHEMICAL PHARMACOLOGY. 2002;64(1):159
Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity -: Effects on thioredoxin reductase and glutathione reductase (vol 63, pg 1875, 2002)
Björkhem-Bergman L; Jönsson K; Eriksson LC; Olsson JM; Lehmann S; Paul C; Björnstedt M
Published conference paper: CLINICAL CANCER RESEARCH. 2001;7(2):367-373
Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells
Lehmann S; Paul C; Törmä H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2000;108(1):198-199
The retinoic acid syndrome in non-M3 acute myeloid leukaemia: A case report
Lehmann S; Paul C
Review: LAKARTIDNINGEN. 1999;96(50):5626-5628
[Arsenic efficient in acute promyelocytic leukemia].
Lehmann S; Paul C

Employments

Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2023-2026

Degrees and Education

Docent, Karolinska Institutet, 2010
Doctor Of Philosophy, Department of Medicine, Huddinge, Karolinska Institutet, 2002
University Medical Degree, Karolinska Institutet, 1992

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI